| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $59K | — | +0.0% |
| R&D Expense | $210K | — | — |
| SG&A Expense | $232K | — | +1641.6% |
| Operating Income | -$552K | — | -798.7% |
| Pre-tax Income | -$968K | — | -87.8% |
| Income Tax | $0 | — | — |
| Net Income | -$968K | — | -87.8% |
| EPS (Basic) | -$0.01 | — | +92.3% |
| EPS (Diluted) | -$0.01 | — | +92.3% |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $5K | -93.4% | +3291.1% |
| Accounts Receivable | $232K | +13.4% | +89.9% |
| Current Assets | $237K | -13.7% | +36.5% |
| Total Assets | $237K | -13.7% | +23.9% |
| Current Liabilities | $6.8M | +3.9% | +16.0% |
| Total Liabilities | $6.8M |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$198K | — | -198.2% |
| Financing Cash Flow | $133K | — | +102.1% |
| +16.0% |
| Stockholders' Equity | -$6.6M | -4.6% | -15.7% |